Skip to main content

NICE TAs

18/05/2020
TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
18/05/2020
TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
18/05/2020
TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
18/05/2020
TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
18/05/2020
TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
18/05/2020
TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
18/05/2020
TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
15/05/2020
TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
13/05/2020
TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
13/05/2020
TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
13/05/2020
TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
13/05/2020
TA434: Elotuzumab for previously treated multiple myeloma (terminated appraisal)
13/05/2020
TA408: Pegaspargase for treating acute lymphoblastic leukaemia
13/05/2020
TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
13/05/2020
TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
13/05/2020
TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
05/05/2020
TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
05/05/2020
TA417 : Nivolumab for previously treated advanced renal cell carcinoma
05/05/2020
TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
04/05/2020
TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Follow AWTTC: